BOSTON, Sept. 26, 2024 (GLOBE NEWSWIRE) — Cue Biopharma , Inc. (Nasdaq: NASDAQ:), a clinical-stage biopharmaceutical firm growing a novel class of therapeutic biologics to selectively interact and modulate disease-specific T cells, in the present day introduced the pricing of an underwritten public providing of (i) 11,564,401 shares of its frequent inventory and accompanying frequent inventory warrants to buy an mixture of two,891,100 shares of frequent inventory and, (ii) to sure buyers in lieu of frequent inventory, pre-funded warrants to buy 12,435,599 shares of frequent inventory and accompanying frequent inventory warrants to buy an mixture of three,108,900 shares of frequent inventory. Every share of frequent inventory and accompanying frequent inventory warrant are being offered collectively at a mixed public providing price of $0.50, and every pre-funded warrant and accompanying frequent inventory warrant are being offered collectively at a mixed public providing price of $0.499. The combination gross proceeds of the providing are anticipated to be roughly $12.0 million, earlier than deducting underwriting reductions and commissions and different providing bills. Every pre-funded warrant can have an train price of $0.001 per share, will probably be exercisable instantly and will probably be exercisable till the entire pre-funded warrants are exercised in full. Every frequent inventory warrant can have an train price of $0.50 per share, will probably be exercisable instantly and can expire 5 years from the date of issuance. The providing is anticipated to shut on or about September 30, 2024, topic to satisfaction of customary closing situations. The entire securities are being provided by Cue Biopharma.
Oppenheimer & Co. Inc. is appearing as sole book-running supervisor for the providing. Newbridge Securities Company is appearing as co-manager for the providing.
A shelf registration assertion on Type S-3 (File No. 333-271786) referring to the securities to be provided within the public providing was filed with the Securities and Change Fee (the SEC) on Could 9, 2023 and declared efficient on Could 26, 2023. The providing was made solely via a prospectus complement and accompanying prospectus that type part of the registration assertion. A preliminary prospectus complement referring to and describing the phrases of the providing has been filed with the SEC and could also be obtained free of charge by visiting the SEC’s web site at www.sec.gov. A closing prospectus complement referring to the providing will probably be filed with the SEC. When obtainable, copies of the preliminary prospectus complement and closing prospectus complement referring to the providing can also be obtained by contacting: Oppenheimer & Co. Inc., Consideration: Syndicate Prospectus Division, 85 Broad Avenue, twenty sixth Flooring, New York, New York 10004, by phone at (212) 667-8055, or by e-mail at EquityProspectus@opco.com.
This press release doesn’t represent a proposal to promote, or a solicitation of a proposal to purchase these securities, nor shall there be any sale of, these securities in any state or jurisdiction through which such provide, solicitation or sale could be illegal previous to registration or qualification beneath the securities legal guidelines of any such state or jurisdiction.
About Cue Biopharma
Cue Biopharma, a clinical-stage biopharmaceutical firm, is growing a novel class of injectable biologics to selectively interact and modulate disease-specific T cells straight inside the affected person’s physique. The corporate’s proprietary platform, Immuno-STAT™ (Selective Concentrating on and Alteration of T cells), and biologics are designed to harness the healing potential of the physique’s intrinsic immune system via the selective modulation of disease-specific T cells with out the antagonistic results of broad systemic immune modulation.
Headquartered in Boston, Massachusetts, we’re led by an skilled administration group and unbiased Board of Administrators with deep experience in immunology and immuno-oncology in addition to the design and scientific improvement of protein biologics.
Cautionary Notice Concerning Ahead-Wanting Statements
This press release comprises forward-looking statements inside the that means of the Personal Securities Litigation Reform Act of 1995. Such forward-looking statements embrace, however should not restricted to, these relating to: the proposed public providing, together with the satisfaction of customary closing situations referring to the providing and the anticipated closing of the general public providing. Ahead-looking statements, that are based mostly on sure assumptions and describe the corporate’s future plans, methods and expectations, can usually be recognized by way of forward-looking phrases resembling anticipate, imagine, proceed, might, estimate, anticipate, aim, intend, might, plan, potential, predict, challenge, search, ought to, goal, will, would or different comparable phrases, though not all forward-looking statements include these figuring out phrases.
Cue Biopharma might not truly obtain the plans, intentions or expectations disclosed in its forward-looking statements, and you shouldn’t place undue reliance on its forward-looking statements. Precise outcomes or occasions might differ materially from the plans, intentions and expectations disclosed within the forward-looking statements Cue Biopharma makes because of numerous dangers and uncertainties, together with however not restricted to the satisfaction of customary closing situations associated to the general public providing, Cue Biopharma’s restricted working historical past, restricted money and a historical past of losses, Cue Biopharma’s capacity to attain profitability, potential setbacks in Cue Biopharma’s research and improvement efforts together with damaging or inconclusive outcomes from its preclinical research or scientific trials or Cue Biopharma’s capacity to duplicate in later scientific trials optimistic outcomes present in preclinical research and early-stage scientific trials of its product candidates and different dangers and uncertainties described within the Danger Elements and Administration’s Dialogue and Evaluation of Monetary Situation and Outcomes of Operations sections of Cue Biopharma’s most just lately filed Annual Report on Type 10-Okay and any subsequently filed Quarterly Experiences on Type 10-Q. Any forward-looking assertion made by Cue Biopharma on this press release is predicated solely on data at present obtainable to Cue Biopharma and speaks solely as of the date on which it’s made. Cue Biopharma undertakes no obligation to publicly replace any forward-looking assertion, whether or not written or oral, which may be made once in a while, whether or not because of new data, future developments or in any other case.
Investor Contact
Marie Campinell
Senior Director, Company Communications
Cue Biopharma, Inc.
mcampinell@cuebio.com
Media Contact
Jonathan Pappas
LifeSci Communications
jpappas@lifescicomms.com
Supply: Cue Biopharma, Inc.